Program
dexamethasone phosphate
Also written as “Moxidex otic solution”, “Dexamethasone sodium phosphate” and “Dexamethasone Phosphate Ophthalmic Solution”.
Its studies are mostly in Otitis Media · Ataxia Telangiectasia · Peripheral Arterial Disease · Uveitis, Anterior · Cataract, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eyegate Pharmaceuticals | 70 open or running | phase 3since May 20, 2010 | Jun 5, 2008 | none ahead |
| Alcon | 60 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Quince Therapeutics | 30 open or running | phase 3since Dec 11, 2023 | Jul 28, 2010 | none ahead |
| Mercator MedSystems | 20 open or running | phase 4since Nov 4, 2013 | Nov 4, 2013 | none ahead |
| Taiwan Liposome | 20 open or running | phase 2since Nov 13, 2013 | Nov 13, 2013 | none ahead |
Also a collaborator on its studies: biotrial.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Dec 19, 2007.
- Oct 2, 2008Phase 2 study in Dry Eye SyndromesEyegate Pharmaceuticals · NCT00765804 · 89 enrolled · United States
- Feb 18, 2010Phase 3 study in Otitis MediaAlcon · NCT01071902 · 400 enrolled · United States
- May 20, 2010Phase 3 study in Dry Eye SyndromesEyegate Pharmaceuticals · NCT01129856 · 198 enrolled · United States
- Jul 28, 2010Quince Therapeutics's first study: phase 2 study in Colitis, UlcerativeNew to Quince TherapeuticsQuince Therapeutics · NCT01171807 · 33 enrolled · Italy
- Nov 4, 2013Mercator MedSystems's first study: phase 4 study in Peripheral Arterial DiseaseNew to Mercator MedSystemsMercator MedSystems · NCT01983449 · 285 enrolled · United States
- Nov 13, 2013Taiwan Liposome's first study: phase 2 study in Macular EdemaNew to Taiwan LiposomeTaiwan Liposome · NCT02006147 · 14 enrolled · Taiwan
- Aug 5, 2015Phase 3 study in Uveitis, AnteriorEyegate Pharmaceuticals · NCT02517619 · 251 enrolled · United States
- Oct 6, 2015Phase 2 study in Patients Having Undergone Unilateral Cataract Extraction and Implantation of a MonofocalEyegate Pharmaceuticals · NCT02571556 · 80 enrolled · United States
- Dec 22, 2015Phase 1 study in VitrectomyEyegate Pharmaceuticals · NCT02644694 · 10 enrolled · United States
- Mar 22, 2017Phase 2 study in Retinal Vein OcclusionTaiwan Liposome · NCT03093701 · 31 enrolled · United States
- Jun 5, 2017Phase 2 study in CataractEyegate Pharmaceuticals · NCT03180255 · 101 enrolled · United States
- May 6, 2019Phase 2 study in Peripheral Arterial DiseaseMercator MedSystems · NCT03942601 · 10 enrolled · United States
- Dec 11, 2023Phase 3 study in Ataxia TelangiectasiaQuince Therapeutics · NCT06193200 · 105 enrolled · United States, Denmark, Germany and more
- Oct 25, 2024Phase 3 study in Ataxia TelangiectasiaQuince Therapeutics · NCT06664853 · 101 enrolled · United States, Denmark, Germany and more
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06664853Ataxia Telangiectasia · United States, Denmark, Germany and more | 3 | Terminated | Quince Therapeutics | Jan 30, 2026 | 101 |
| NCT06193200Ataxia Telangiectasia · United States, Denmark, Germany and more | 3 | Completed | Quince Therapeutics | Dec 17, 2025 | 105 |
| NCT03942601Peripheral Arterial Disease · United States | 2 | Terminated | Mercator MedSystems | Apr 30, 2021 | 10 |
| NCT03180255Cataract · United States | 2 | Completed | Eyegate Pharmaceuticals | Nov 7, 2017 | 101 |
| NCT03093701Retinal Vein Occlusion · United States | 2 | Completed | Taiwan Liposome | Feb 4, 2019 | 31 |
| NCT02644694Vitrectomy · United States | 1 | Completed | Eyegate Pharmaceuticals | Oct 2016 | 10 |
| NCT02571556Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal · United States | 2 | Completed | Eyegate Pharmaceuticals | Oct 2016 | 80 |
| NCT02517619Uveitis, Anterior · United States | 3 | Completed | Eyegate Pharmaceuticals | Apr 20, 2018 | 251 |
| NCT02006147Macular Edema · Taiwan | 2 | Completed | Taiwan Liposome | Jul 15, 2020 | 14 |
| NCT01983449Peripheral Arterial Disease · United States | 4 | Completed | Mercator MedSystems | Dec 2016 | 285 |
| NCT01171807Colitis, Ulcerative · Italy | 2 | Completed | Quince Therapeutics | May 15, 2007 | 33 |
| NCT01129856Dry Eye Syndromes · United States | 3 | Completed | Eyegate Pharmaceuticals | Jan 2011 | 198 |
| NCT01071902Otitis Media · United States | 3 | Terminated | Alcon | Oct 2011 | 400 |
| NCT00765804Dry Eye Syndromes · United States | 2 | Completed | Eyegate Pharmaceuticals | Feb 2009 | 89 |
| NCT00750633Otitis Externa | 3 | Completed | Alcon | Jan 2009 | 990 |
| NCT00694135Uveitis, Anterior · United States, India | 2 | Completed | Eyegate Pharmaceuticals | Jul 2009 | 40 |
| NCT00579189Otitis Media | 3 | Completed | Alcon | Jan 2009 | 776 |
| NCT00579020Corneal Diseases · United States | 2 | Terminated | Alcon | Feb 2009 | 144 |
| NCT00578773Otitis Media | 2 | Completed | Alcon | Jan 2009 | 303 |
| NCT00578474Otitis Media | 3 | Completed | Alcon | Aug 2008 | 911 |
How it is read
Names in the registry
- “Moxidex otic solution”, 5 entries
- “Dexamethasone sodium phosphate”, 2 entries
- “Dexamethasone Phosphate Ophthalmic Solution”, 2 entries
- “Low-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
- “High-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
Conditions, from the studies’ own filings
- Otitis Media, 4 studies
- Ataxia Telangiectasia, 2 studies
- Peripheral Arterial Disease, 2 studies
- Uveitis, Anterior, 2 studies
- Cataract, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.